Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Analyst: Cryptocurrencies Tend to Adjust Before Fed Meetings, Pullback May End and Rebound Start on Tuesday

Analyst: Cryptocurrencies Tend to Adjust Before Fed Meetings, Pullback May End and Rebound Start on Tuesday

BlockBeatsBlockBeats2025/05/04 22:03
Show original

According to Cointelegraph, crypto analyst Michaël van de Poppe stated, "Despite the recent strong rebound in Bitcoin, there is still enough room to retest the support level. I would prefer to see Bitcoin remain above $91,500 to $92,000. For me, this would confirm the continuation of the upward trend, as the previous range support becomes effective support again, indicating a potential to continue challenging the all-time high (ATH). Cryptocurrencies and altcoins tend to adjust in the week leading up to the Federal Reserve meeting, and it is speculated that this round of adjustment will end around Tuesday, after which a rebound will begin."

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.